Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine therapy in obsessive-compulsive disorder (cross-over trial)
2024-518212-40-00Phase 3Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ketamine in obsessive compulsive disorder (OCD), sponsored by Medical University of Vienna. Planned start Oct 2024; status: authorised.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2024-518212-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518212-40-00.